About Atreca
Atreca is a company based in San Carlos (United States) founded in 2010. Atreca has raised $224.4 million across 9 funding rounds from investors including Gates Foundation, GSK and Tekla Capital Management. The company has 134 employees as of December 31, 2021. Atreca operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Carlos, United States
- Employees 134 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Atreca, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$224.4 M (USD)
in 9 rounds
-
Latest Funding Round
$125 M (USD), Series C
Sep 12, 2018
-
Investors
Gates Foundation
& 9 more
-
Employee Count
134
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Atreca
Unlock access to complete
Unlock access to complete
Funding Insights of Atreca
Atreca has successfully raised a total of $224.4M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Atreca
Atreca has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, GSK and Tekla Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Atreca
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Atreca
Investment portfolio details for Atreca
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Atreca
Detailed financials for Atreca
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atreca Comparisons
Peer comparison for Atreca
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Atreca
Atreca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Atreca
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atreca
Complete news archive for Atreca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atreca
Atreca was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Atreca is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Atreca is a funded company, having raised a total of $224.4M across 9 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Atreca is 134.
Developer of antibody therapeutics for human anti-cancer immune responses. Atrecas proprietary Immune Repertoire Capture technology profiles a patients immune response at the single-cell level, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. Its technology can be used for the discovery and development of antibody-based therapeutics and for identifying the critical targets of effective immune responses. It is applying its technology to generate and develop a novel class of cancer immunotherapies including therapeutics that optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.
Atreca's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Atreca has 10 investors. Key investors include Gates Foundation, GSK, Tekla Capital Management, Wellington, and Aisling Capital.